1025 related articles for article (PubMed ID: 20088621)
1. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Alzheimer's disease.
Birks J
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
[TBL] [Abstract][Full Text] [Related]
3. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
5. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
6. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
10. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
[TBL] [Abstract][Full Text] [Related]
11. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
12. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Wattmo C; Wallin AK; Minthon L
BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
[TBL] [Abstract][Full Text] [Related]
13. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
[TBL] [Abstract][Full Text] [Related]
14. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
15. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
16. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
17. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
18. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
19. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]